220 related articles for article (PubMed ID: 11740974)
1. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
Bonaccorso S; Puzella A; Marino V; Pasquini M; Biondi M; Artini M; Almerighi C; Levrero M; Egyed B; Bosmans E; Meltzer HY; Maes M
Psychiatry Res; 2001 Dec; 105(1-2):45-55. PubMed ID: 11740974
[TBL] [Abstract][Full Text] [Related]
2. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Verkerk R; Meltzer H; Maes M
J Clin Psychopharmacol; 2002 Feb; 22(1):86-90. PubMed ID: 11799348
[TBL] [Abstract][Full Text] [Related]
3. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
Maes M; Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Meltzer H
Mol Psychiatry; 2001 Jul; 6(4):475-80. PubMed ID: 11443537
[TBL] [Abstract][Full Text] [Related]
4. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
[TBL] [Abstract][Full Text] [Related]
5. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
Maes M; Capuron L; Ravaud A; Gualde N; Bosmans E; Egyed B; Dantzer R; Neveu PJ
Neuropsychopharmacology; 2001 Feb; 24(2):130-40. PubMed ID: 11120395
[TBL] [Abstract][Full Text] [Related]
6. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C.
Maes M; Bonaccorso S
Acta Psychiatr Scand; 2004 Feb; 109(2):126-31. PubMed ID: 14725594
[TBL] [Abstract][Full Text] [Related]
7. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K
Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951
[TBL] [Abstract][Full Text] [Related]
8. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
Capuron L; Ravaud A; Dantzer R
J Clin Oncol; 2000 May; 18(10):2143-51. PubMed ID: 10811680
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
Neri S; Pulvirenti D; Bertino G
Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
Vignau J; Karila L; Costisella O; Canva V
Encephale; 2005; 31(3):349-57. PubMed ID: 16142050
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
Wichers MC; Kenis G; Koek GH; Robaeys G; Nicolson NA; Maes M
J Psychosom Res; 2007 Feb; 62(2):207-14. PubMed ID: 17270579
[TBL] [Abstract][Full Text] [Related]
13. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
Capuron L; Ravaud A; Gualde N; Bosmans E; Dantzer R; Maes M; Neveu PJ
Psychoneuroendocrinology; 2001 Nov; 26(8):797-808. PubMed ID: 11585680
[TBL] [Abstract][Full Text] [Related]
14. Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-α and Ribavirin Treatment in Chronic Hepatitis Patients.
Frydecka D; Pawłowski T; Pawlak D; Małyszczak K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):169-175. PubMed ID: 28083615
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
Kenis G; Prickaerts J; van Os J; Koek GH; Robaeys G; Steinbusch HW; Wichers M
Int J Neuropsychopharmacol; 2011 Mar; 14(2):247-53. PubMed ID: 20667172
[TBL] [Abstract][Full Text] [Related]
16. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue.
Felger JC; Alagbe O; Pace TW; Woolwine BJ; Hu F; Raison CL; Miller AH
Brain Behav Immun; 2011 Aug; 25(6):1094-8. PubMed ID: 21356304
[TBL] [Abstract][Full Text] [Related]
17. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
Kraus MR; Schäfer A; Csef H; Scheurlen M
World J Gastroenterol; 2005 Mar; 11(12):1769-74. PubMed ID: 15793861
[TBL] [Abstract][Full Text] [Related]
19. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
20. Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C.
Małyszczak K; Inglot M; Frydecka D; Hadryś T; Pawłowski T
Adv Clin Exp Med; 2019 Sep; 28(9):1217-1222. PubMed ID: 30811903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
